| Ticker Details |
Veracyte, Inc.
Veracyte Inc is a molecular diagnostics company that uses genomic technology to resolve diagnostic ambiguity. The Company's first commercial solution, the Afirma Thyroid FNA Analysis, centers on the proprietary Afirma Gene Expression Classifier.
|
| IPO Date: |
October 30, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.49B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.58 | 2.51%
|
| Avg Daily Range (30 D): |
$0.60 | 1.80%
|
| Avg Daily Range (90 D): |
$0.68 | 1.77%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.4M |
| Avg Daily Volume (30 D): |
.72M |
| Avg Daily Volume (90 D): |
.62M |
| Trade Size |
| Avg Trade Size (Sh.): |
62 |
| Avg Trade Size (Sh.) (30 D): |
52 |
| Avg Trade Size (Sh.) (90 D): |
49 |
| Institutional Trades |
| Total Institutional Trades: |
3,661 |
| Avg Institutional Trade: |
$2.8M |
| Avg Institutional Trade (30 D): |
$4.1M |
| Avg Institutional Trade (90 D): |
$4.05M |
| Avg Institutional Trade Volume: |
.09M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.15M |
| Avg Closing Trade (30 D): |
$7.59M |
| Avg Closing Trade (90 D): |
$6.98M |
| Avg Closing Volume: |
137.31K |
|
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$.84
|
$.52
|
$.84
|
|
Diluted EPS
|
$.82
|
$.5
|
$.82
|
|
Revenue
|
$517.15M
|
$140.64M
|
$517.15M
|
|
Gross Profit
|
$362.53M
|
$101.97M
|
$362.53M
|
|
Net Income / Loss
|
$66.35M
|
$41.15M
|
$66.35M
|
|
Operating Income / Loss
|
$57.78M
|
$37.2M
|
$57.78M
|
|
Cost of Revenue
|
$154.61M
|
$38.66M
|
$154.61M
|
|
Net Cash Flow
|
$123.6M
|
$47.02M
|
$123.6M
|
|
PE Ratio
|
37.91
|
|
|
|
|
|
